Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects

NCT04112992 · tracked via the Priya Life Science India tracker
Phase
Observational
Started
2024-07-03
Last updated
2025-08-29

Condition(s) studied

Limb FractureBone Loss

Investigational drug(s) / intervention(s)

Any treatment that is used for a defect of any long bone

Any treatment that is used for a defect of any long bone: Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.

Study summary

Long bone defect (LBD) is defined as a focalized loss of bone tissue in any long bone of the upper or lower extremity. Long bone defects are a complex problem, that may arise as a complication of many different pathologies, such as trauma, tumors or infection. Whereas post-traumatic defects are the largest group.

Reports estimate that there are almost 4 million bone grafting procedures worldwide per year. However, limb reconstruction in the context of a bony defect is challenging and up to date there is little evidence and treatment recommendations.

In a multi-national approach, the aim of this project is to set up an international, multicenter registry to gather information and details on prevalence or incidence, current treatments, complications and outcome.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Skeletally mature * Post traumatic bone defect \> 2 cm either * initially after injury or * after surgical debridement * Informed consent obtained, i.e.: * Ability to understand the content of the patient information/ICF * Willingness and ability to participate in the clinical investigation according to the registry plan * Signed and dated EC/IRB approved written informed consent OR * Written consent provided according to the IRB/EC defined and approved procedures for patients who are not able to provide independent written informed consent Exclusion Criteria: * Any oblique defect that has less than 8cm expansion when adding the defect size of all four cortices * Any not medically managed severe systemic disease * Pregnancy * Prisoners * Participation in any other medical device or medicinal product registry within the previous 3 months that could influence the results of the present registry

Primary outcome measure(s)

  • Baseline characteristics — Pre-operative
    Demographics, medical history, comorbidity
  • Bone defect details — Pre-operative and/or intraoperative
    * Affected bone * Localization: Proximal 1/3rd, middle 3rd, distal 1/3rd(for any bone) * Size (categorization according Karger classification; definition: a bone defect should be at least 2 cm (Karger Type II)) Type II: 2-5 cm Type III: 5-10 cm Type IV: \> 10 cm
  • Trauma assessment — Pre-operative and/or intraoperative
    * Injury Severity Score (ISS): Grading for each item (points): No injury (0), Minor (1), Moderate (4), Serious (9), Severe (16), Critical (25), Unsurvivable (75) * Assessment: * Head and neck worst injury * Face worst injury * Chest worst injury * Abdomen worst injury * Extremity (including pelvis) worst injury * External worst injury * Gustilo \& Anderson classification for open fractures * Type I * Type II * Type IIIA * Type IIIB * Type IIIC * Tscherne classification for closed fracture and soft-tissue injuries * Grade 0 * Grade 1 * Grade 2 * Grade 3
  • evaluate the bone defect in the context of previous interventions — Intraoperative
    Number of previous interventions: \<2, \<4, \>4
  • Surgical details & Intraoperative findings 1 — Intraoperative
    * Procedure type: * One stage * Staged (e.g. Masquelet technique / distraction osteogenesis / bone transport) * Ilizarov * Bone quality (good, fair, poor) by surgeon's discretion * Soft tissue and vascularity (good, fair, poor) by surgeon's discretion * Contamination (yes/no) Specification: * Metal from a bullet * Metal from a pole * Other Metal * Wood * Soil * Others * Surgical time (min) * Stabilization technique: Internal device (extra- or intramedullary) / External device (For both, drop down menu will be used)
  • Surgical details & Intraoperative findings 2 — Intraoperative
    * Bone grafting * Autografts * Allograft(s) * Other synthetics * If applicable - time to harvest graft (in minutes) * Graft enhancement yes / no * Demineralized bone matrix (DBM) * Bone morphogenetic protein (BMP) * Stem cells * Platelet rich plasma (PRP) * Other * Soft-tissue / vascular / microsurgical procedure yes / no * Skin graft * Local flap * Free flap * Additional treatment * Systemic antibiotic treatment yes / no * Local antibiotic treatment yes / no * Post-operative use of a negative pressure dressings (NPWT) or vacuum-assisted closure (VAC) system yes / no
  • Functional Outcome — 6 months follow-up / 12 months follow-up and/or 6 months after bone union (max 12 months)
    \- Assessment of limb function and loss of length * Definition: anatomic shortening of the limb in comparison to the contralateral side * Assessment in cm * Any orthotic used to equalize leg length
  • Patient related outcome / Quality of life 1 — Screening / 6 months follow-up / 12 months follow-up and/or 6 months after bone union (max 18 months)
    Patient-Reported Outcomes Measurement Information System (PROMIS) * Physical function: This item measures self-reported capability rather than actual performance. It includes the functioning of lower extremities (walking or mobility) as well as instrumental activities of daily living, such as running errands. We will use the short form 10b. * Physical function, upper extremity: This item measures activities that require use of the upper extremity including shoulder, arm, and hand activities. Examples include writing, using buttons, or opening containers. We will use the short form 7. * Pain Interference: This item assesses self-reported consequences of pain on relevant aspects of one's life. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. We will use the short form 8a. Short forms will be used in all sites possible (i.e. where the translation is available).
  • Patient related outcome / Quality of life 2 — Screening / 6 months follow-up / 12 months follow-up and/or 6 months after bone union (max 18 months)
    EQ-5D-3L assessment (Five items, 3-point categorical scale) The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. o The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.
  • Radiological Outcome — Screening / / Intraoperative / 6 months follow-up / 12 months follow-up and/or 6 months after bone union (max 18 months)
    Pre-operative/intraoperative * Deformity parameters (if applicable) * Nonunion classification: Hypertrophic, Oligotrophic, Atrophic Follow-up visits * Bone healing (based on the treating physician's judgement): Not healed / Partially healed / Mostly healed / Healed * Evaluation of the expansion of the bone defect: bone defect size * Time to healing: Date when full healing is achieved (to be calculated days from index surgery)

Trial sites (21)

FacilityCityRegionStatus
Cedar Sinai Los Angeles California Recruiting
Sinai Hospital of Baltimore Baltimore Maryland Recruiting
John Hunter Hospital Newcastle Australia Recruiting
Hospital Municipal Miguel Couto Serviço de Ortopedia e Traumatologia Rio de Janeiro Brazil Recruiting
Hospital Base Valdivia Valdivia Chile Recruiting
Hospital Universitario de la Samaritana Bogotá Colombia Suspended
Hospital Pablo Tobon Uribe Medellín Colombia Recruiting
University Hospital Frankfurt Frankfurt Germany Recruiting
Universitätsspital Gießen Giessen Germany Recruiting
Universitätsklinikum Heidelberg (Unfallchirurgie) Heidelberg Germany Terminated
Universitätsklinikum Münster (Klinik und Poliklinik für Unfall-, Hand- und Wiederherstellungschirurgie) Münster Germany Recruiting
Krankenhaus Johanneum Wildeshausen Germany Not Yet Recruiting
Paras HMRI Hospital Patna Patna India Recruiting
Academisch Ziekenhuis Maastricht (Dept. of Surgery) Maastricht Netherlands Recruiting
Radboud University Medical Center Nijmegen Netherlands Recruiting
Tygerberg Hospital Cape Town South Africa Not Yet Recruiting
Kyungpook National University Hospital (Orthopaedics) Daegu South Korea Recruiting
Universitätsspital Zürich (Klinik für Traumatologie) Zurich Switzerland Recruiting
Central Hospital of Border Guard Service of Ukraine Kyiv Ukraine Not Yet Recruiting
Leeds General Infirmary University Hospital (Trauma & Orthopaedic Surgery) Leeds United Kingdom Not Yet Recruiting
Hospital Universitario de Caracas Caracas Venezuela Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04112992 on ClinicalTrials.gov ↗ ← All trials in India